Literature DB >> 14754951

Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.

Philip Sanford Zeskind1, Laura E Stephens.   

Abstract

OBJECTIVE: This is a prospective study of the effects of maternal use of selective serotonin reuptake inhibitors (SSRIs) during pregnancy on newborn neurobehavioral integrity, including systematic measures of behavioral state, sleep organization, motor activity, heart rate variability (HRV), tremulousness, and startles.
METHODS: The sample included 17 SSRI-exposed and 17 nonexposed, full-birth-weight newborn infants who had no obvious medical problems and were matched on maternal cigarette use, social class, and maternal age. SSRI exposure was determined by medical records and maternal self-report during a standard interview. Behavioral state, startles, and tremulousness were evaluated for 1 hour between feedings. Automated recordings of motor activity and HRV were also assessed during a 15-minute subset sleep period. HRV was subjected to spectral analysis to detect rhythms in autonomic regulation. Exposed and nonexposed infant groups were compared on measures of neurobehavioral development both before and after adjustment for gestational age as a covariate.
RESULTS: SSRI-exposed infants had a shorter mean gestational age; were more motorically active and tremulous; and showed fewer rhythms in HRV, fewer changes in behavioral state, fewer different behavioral states, and a lower peak behavioral state. SSRI-exposed infants also had significantly more rapid eye movement sleep, which was characterized by longer continuous bouts in that state and higher numbers of spontaneous startles or sudden arousals. After effects of gestational age were covaried, significant differences continued to be found in tremulousness and all measures of state and sleep organization, but effects on startles, motor activity, and rhythms in HRV were no longer significant.
CONCLUSIONS: Results provide the first systematic evidence that women who use SSRIs during pregnancy have healthy, full-birth-weight newborn infants who show disruptions in a wide range of neurobehavioral outcomes. Effects on motor activity, startles, and HRV may be mediated through the effects of SSRI exposure on gestational age. Future research can lead to a better understanding of the effects of SSRI use during pregnancy and an improved public health outcome.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14754951     DOI: 10.1542/peds.113.2.368

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  63 in total

1.  A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction.

Authors:  Nancy K Grote; Jeffrey A Bridge; Amelia R Gavin; Jennifer L Melville; Satish Iyengar; Wayne J Katon
Journal:  Arch Gen Psychiatry       Date:  2010-10

2.  Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment.

Authors:  Albert Putzhammer; Anja Schoeler; Thomas Rohrmeier; Philipp Sand; Goeran Hajak; Peter Eichhammer
Journal:  Psychopharmacology (Berl)       Date:  2004-08-18       Impact factor: 4.530

Review 3.  Investigating outcomes following the use of selective serotonin reuptake inhibitors for treating depression in pregnancy: a focus on methodological issues.

Authors:  Luke E Grzeskowiak; Andrew L Gilbert; Janna L Morrison
Journal:  Drug Saf       Date:  2011-11-01       Impact factor: 5.606

4.  Depression during pregnancy.

Authors:  Donna Stewart
Journal:  Can Fam Physician       Date:  2005-08       Impact factor: 3.275

5.  Concerns regarding antidepressant drug use during pregnancy.

Authors:  Adam C Urato
Journal:  J Psychiatry Neurosci       Date:  2006-11       Impact factor: 6.186

6.  Mood disorders and their pharmacological treatment during pregnancy: is the future child affected?

Authors:  Catherine Monk; Elizabeth M Fitelson; Elizabeth Werner
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

7.  Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development.

Authors:  Regina C Casper; Allyson A Gilles; Barry E Fleisher; Joan Baran; Gregory Enns; Laura C Lazzeroni
Journal:  Psychopharmacology (Berl)       Date:  2011-04-16       Impact factor: 4.530

8.  Neonatal effects of exposure to selective serotonin reuptake inhibitors during pregnancy.

Authors:  P Bot; B A Semmekrot; J van der Stappen
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-03       Impact factor: 5.747

Review 9.  [Drug therapy during pregnancy].

Authors:  C Schaefer; C Weber-Schoendorfer
Journal:  Internist (Berl)       Date:  2009-04       Impact factor: 0.743

Review 10.  Developmental changes in serotonin signaling: Implications for early brain function, behavior and adaptation.

Authors:  S Brummelte; E Mc Glanaghy; A Bonnin; T F Oberlander
Journal:  Neuroscience       Date:  2016-02-22       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.